Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.47 |
| ▸ | MTOR | P42345 | 3/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 3/20 | 0.45 |
| ▸ | LITAF | Q99732 | 3/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21593644 | 1.00 | PIK3CA (0.47) | PIK3CAMTORPRKDCHSD11B1TNF | |
| SCHEMBL21593726 | 1.00 | PIK3CA (0.47) | PIK3CAMTORPRKDCHSD11B1TNF | |
| SCHEMBL21593686 | 0.94 | PIK3CA (0.52) | PIK3CAMTORPRKDCTNFLITAF | |
| SCHEMBL29153725 | 0.89 | PIK3CA (0.41) | PIK3CAMTORPRKDCTNFLITAF | |
| SCHEMBL29153724 | 0.89 | PIK3CA (0.41) | PIK3CAMTORPRKDCTNFLITAF | |
| SCHEMBL21593718 | 0.89 | PIK3CA (0.41) | PIK3CAMTORPRKDCTNFLITAF | |
| SCHEMBL23452654 | 0.86 | PRKDC (0.44) | PIK3CAMTORPRKDCHSD11B1ATM | |
| SCHEMBL28519123 | 0.86 | PRKDC (0.44) | PIK3CAMTORPRKDCHSD11B1ATM | |
| SCHEMBL21591887 | 0.86 | PRKDC (0.44) | PIK3CAMTORPRKDCHSD11B1ATM | |
| SCHEMBL2636985 | 0.84 | HSD11B1 (0.62) | PIK3CAMTORPRKDCHSD11B1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | disclosed |
| CN-112236431-B | Purinone Compounds and Their Use in the Treatment of Cancer | 阿斯利康(瑞典)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2024-01-30 | — | — | US | disclosed |
| EP-3807278-B1 | PURINONE DERIVATIVES AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-08-31 | — | — | EP | disclosed |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| CN-112236431-A | Purinone compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | PIK3CA 1179/4885MTOR 1844/4885PRKDC 274/4885 |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | PIK3CA 1081/4885MTOR 1496/4885PRKDC 337/4885 |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | RECQL, PRPS1, PURB | PIK3CA 1179/4885MTOR 1844/4885PRKDC 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.